Clinuvel Pharmaceuticals 관리

관리 기준 확인 2/4

Clinuvel Pharmaceuticals CEO는 Philippe Wolgen, Nov2005 에 임명되었습니다 의 임기는 19.08 년입니다. 총 연간 보상은 A$ 3.74M, 47.2% 로 구성됩니다. 47.2% 급여 및 52.8% 보너스(회사 주식 및 옵션 포함). 는 € 27.47M 가치에 해당하는 회사 주식의 6.86% 직접 소유합니다. 27.47M. 경영진과 이사회의 평균 재임 기간은 각각 0.9 년과 5 년입니다.

주요 정보

Philippe Wolgen

최고 경영자

AU$3.7m

총 보상

CEO 급여 비율	47.2%
CEO 임기	19yrs
CEO 소유권	6.9%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Philippe Wolgen 의 보수는 Clinuvel Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$4m	AU$2m	AU$36m
Mar 31 2024	n/a	n/a	AU$33m
Dec 31 2023	n/a	n/a	AU$30m
Sep 30 2023	n/a	n/a	AU$30m
Jun 30 2023	AU$6m	AU$2m	AU$31m
Mar 31 2023	n/a	n/a	AU$29m
Dec 31 2022	n/a	n/a	AU$26m
Sep 30 2022	n/a	n/a	AU$24m
Jun 30 2022	AU$7m	AU$1m	AU$21m
Mar 31 2022	n/a	n/a	AU$22m
Dec 31 2021	n/a	n/a	AU$24m
Sep 30 2021	n/a	n/a	AU$24m
Jun 30 2021	AU$5m	AU$2m	AU$25m
Mar 31 2021	n/a	n/a	AU$23m
Dec 31 2020	n/a	n/a	AU$21m
Sep 30 2020	n/a	n/a	AU$18m
Jun 30 2020	AU$3m	AU$2m	AU$15m
Mar 31 2020	n/a	n/a	AU$15m
Dec 31 2019	n/a	n/a	AU$15m
Sep 30 2019	n/a	n/a	AU$16m
Jun 30 2019	AU$1m	AU$894k	AU$18m
Mar 31 2019	n/a	n/a	AU$17m
Dec 31 2018	n/a	n/a	AU$16m
Sep 30 2018	n/a	n/a	AU$15m
Jun 30 2018	AU$2m	AU$818k	AU$13m

보상 대 시장: Philippe 의 총 보상 ($USD 2.43M )은 German 시장( $USD 1.03M ).

보상과 수익: Philippe 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Philippe Wolgen (61 yo)

19yrs

테뉴어

AU$3,742,412

보상

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....

리더십 팀

이름	위치	테뉴어	보상	소유권
Philippe Wolgen	CEO, MD & Director	19yrs	AU$3.74m	6.86% € 27.5m
Dennis Wright	Chief Scientific Officer	12.2yrs	AU$782.61k	0.38% € 1.5m
Peter Vaughan	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Lachlan Hay	Chief Operations Officer	no data	데이터 없음	데이터 없음
Malcolm Bull	Head of Australian Operations & Investor Relations	no data	데이터 없음	데이터 없음
Rose Quadbeck-Diel	Senior Vice President of Regulatory Affairs	less than a year	데이터 없음	데이터 없음
Azza Hamila	Head of Quality Assurance & Drug Safety	less than a year	데이터 없음	데이터 없음
Claire Newstead-Sinclair	Company Secretary	less than a year	데이터 없음	데이터 없음

0.9yrs

평균 재임 기간

경험이 풍부한 관리: UR9A 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Philippe Wolgen	CEO, MD & Director	19.1yrs	AU$3.74m	6.86% € 27.5m
Pearl Grimes	Non-Executive Director	less than a year	데이터 없음	데이터 없음
Matthew Pringle	Non-Executive Director	less than a year	데이터 없음	데이터 없음
Susan Smith	Non-Executive Director	5.2yrs	AU$80.00k	0.00084% € 3.4k
Jeffrey Rosenfeld	Non-Executive Chairman	5yrs	AU$91.67k	0.0063% € 25.2k
Karen Agersborg	Non-Executive Director	6.8yrs	AU$75.00k	0.028% € 111.0k
Guy van Dievoet	Non-Executive Director	less than a year	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

경험이 풍부한 이사회: UR9A 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

Clinuvel Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Recent updates

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021

Clinuvel Pharmaceuticals Limited Announces First Patient Dosed in SCENESSE DNA Repair Program

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간